trending Market Intelligence /marketintelligence/en/news-insights/trending/bckvree-t3sismut-i4myg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Adaptimmune, Bellicum to collaborate on T-cell therapies

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Adaptimmune, Bellicum to collaborate on T-cell therapies

Adaptimmune Therapeutics PLC and Bellicum Pharmaceuticals Inc. signed a deal to collaborate on the evaluation, development and commercialization of next-generation T-cell therapies.

The companies said they agreed to utilize Adaptimmune's affinity-optimized SPEAR T-cells to evaluate Bellicum's GoTCR technology for the potential to create enhanced T-cell receptor product candidates. Based on the results of the pre-clinical proof-of-concept phase, the companies will move to a two-target co-development and co-commercialization phase.